GlassScriptPhysician profile
Mark J Juska
NPI 1942439567
$7,280.86
in general payments reported to CMS, 2019-2025
35 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,603 · 2020: $193 · 2021: $672 · 2022: $703 · 2023: $590 · 2024: $686 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921 · Travel and Lodging: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.67 |
| Travel and Lodging | $189.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,427.00 | 2019 | |
| Abbott Laboratories | $1,373.79 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $566.37 | 2019-2024 | Senza |
| Medwest Associates | $363.00 | 2019 | |
| Boston Scientific Corporation | $288.83 | 2019-2025 | Intracept, General - Pain Management |
| Spinal Simplicity, LLC | $242.80 | 2024-2025 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $204.48 | 2019-2024 | Xtampza, Belbuca |
| Medtronic, INC. | $146.43 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Teva Pharmaceuticals USA, INC. | $139.01 | 2019-2024 | Ajovy |
| Supernus Pharmaceuticals, INC. | $130.10 | 2019-2020 | |
| Assertio Therapeutics, INC. | $130.08 | 2019-2020 | |
| Pfizer INC. | $128.79 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.73 | 2022 | |
| Si-Bone, INC. | $110.25 | 2021-2022 | |
| Abbvie INC. | $91.25 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $79.99 | 2019-2022 | |
| Grt US Holding, INC. | $77.75 | 2021-2022 | |
| Pacira Therapeutics, INC. | $62.80 | 2019-2021 | |
| Spr Therapeutics, INC | $61.94 | 2024 | Sprint Pns System |
| Novartis Pharmaceuticals Corporation | $59.29 | 2019-2020 | |
| Vertiflex, INC. | $57.98 | 2019 | |
| Stryker Corporation | $57.33 | 2025 | Mild Device Kit |
| Nalu Medical, INC. | $56.74 | 2021-2024 | Nalu Neurostimulation System |
| Allergan, INC. | $56.05 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $51.86 | 2021 | |
| Biodelivery Sciences International, INC. | $31.84 | 2021 | |
| Medtronic USA, INC. | $30.22 | 2019 | |
| Globus Medical, INC. | $25.92 | 2025 | Senza |
| Surgalign Spine Technologies, INC. | $24.16 | 2019 | |
| Fidia Pharma USA INC. | $18.58 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.07 | 2019 | |
| Curonix LLC | $13.61 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Pharmaceuticals Incorporated | $12.12 | 2021 | |
| Depuy Synthes Sales INC. | $11.69 | 2022 | |
| Bioventus LLC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Juska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.